• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Vibegron Intermediate CAS:1421271-01-3
Food Grade Fish Collagen
Vibegron Intermediate CAS:1295539-30-8
Vibegron Intermediate CAS:1426235-01-9
Vibegron Intermediate CAS:163625-46-5
Vibegron Intermediate

EU drug regulator records 415 cases of possible rare blood clotting

firstwordpharmaJune 18, 2021

Tag: AstraZeneca , Johnson & Johnson , COVID-19 , Vaccine

The EU drug regulator said on Thursday it has received reports of 415 possible cases of thrombosis with thrombocytopenia syndrome in the European Economic Area (EEA), out of over 50 million people who have gotten AstraZeneca and Johnson & Johnson's COVID-19 vaccines, as reported in Fidelity.

EU drug regulator records 415 cases of possible rare blood clotting

Specifically, there have been 10 possible cases among just under 6 million people who received Johnson & Johnson's shot in the EEA, and 405 cases among 45 million who received AstraZeneca's shot, stated Georgy Genov, head of pharmacovigilance at the European Medicines Agency.


Previous:Alzamend Neuro Announces Closing of Initial Public Offering and Full Exercise of Underwriter’s Over-allotment Option for Gross Proceeds of $14.4 Million

Next:U.S. Buys 200 Million Extra Moderna Vaccine Doses, as Possible Booster Shots

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

EU drug regulator records 415 cases of possible rare blood clotting | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

Hualan Biological Flu Vaccine

Hualan Biological Flu Vaccine
Influenza Vaccine in Syringe Form

Influenza Vaccine in Syringe Form
*trivalent flu vaccine

*trivalent flu vaccine
2024-2025 trivalent flu vaccine WHO-PQ

2024-2025 trivalent flu vaccine WHO-PQ
Hualan Group ACYW135 Meningococcal Polysaccharide Vaccine with lower side effect and high quality

Hualan Group ACYW135 Meningococcal Polysaccharide Vaccine with lower side effect and high quality
Influenza A (H1N1) Vaccine, (Split, Inactivated)by Hualan biological 1

Influenza A (H1N1) Vaccine, (Split, Inactivated)by Hualan biological 1
Influenza Vaccine(Split Virion),Inactivated

Influenza Vaccine(Split Virion),Inactivated
High-standard Influenza Vaccine (Split virion), inactivated

High-standard Influenza Vaccine (Split virion), inactivated
Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strains

Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strains
Recombinant Hepatitis B Vaccine

Recombinant Hepatitis B Vaccine

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service